Myriad GeneticsMYGN
MYGN
About: Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Employees: 2,700
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,343% more call options, than puts
Call options by funds: $4.1M | Put options by funds: $284K
23% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 74
1.59% more ownership
Funds ownership: 99.88% [Q3] → 101.47% (+1.59%) [Q4]
11% less funds holding
Funds holding: 246 [Q3] → 219 (-27) [Q4]
45% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 56
49% less capital invested
Capital invested by funds: $2.48B [Q3] → $1.27B (-$1.22B) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
48%
upside
Avg. target
$17.36
134%
upside
High target
$29
291%
upside
7 analyst ratings
5 positive
71%
1 neutral
14%
1 negative
14%
Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target | 89%upside $14 | Buy Maintained | 17 Apr 2025 |
Scotiabank Sung Ji Nam 8% 1-year accuracy 2 / 24 met price target | 170%upside $20 | Sector Outperform Maintained | 1 Apr 2025 |
Piper Sandler Dave Weiner 0% 1-year accuracy 0 / 1 met price target | 69%upside $12.50 | Overweight Upgraded | 12 Mar 2025 |
B of A Securities Derik De Bruin 35% 1-year accuracy 7 / 20 met price target | 48%upside $11 | Underperform Maintained | 3 Mar 2025 |
Raymond James Andrew Cooper 28% 1-year accuracy 5 / 18 met price target | 156%upside $19 | Outperform Reiterated | 25 Feb 2025 |
Financial journalist opinion
Based on 6 articles about MYGN published over the past 30 days
Neutral
GlobeNewsWire
18 hours ago
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
More than half say genetic testing for mental health medications could reduce concerns More than half say genetic testing for mental health medications could reduce concerns
Neutral
GlobeNewsWire
5 days ago
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD Podium presentation showcases the clinical application of Precise™ MRD
Neutral
Zacks Investment Research
1 week ago
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035.
Neutral
GlobeNewsWire
1 week ago
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the GeneSight ® Psychotropic Test. “Millions of Americans face major depressive disorder each year, and the GeneSight test provides genetic insights that may help healthcare providers personalize the selection of mental health medications,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics.
Neutral
GlobeNewsWire
3 weeks ago
Myriad Genetics Announces Inducement Awards
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 million, in each case effective as of the first day of his employment. These equity awards are inducements material to Mr. Donnelly's entering into employment with Myriad Genetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 weeks ago
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies.
Positive
Zacks Investment Research
1 month ago
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Positive
Schaeffers Research
1 month ago
Medical Equipment Stock Jumps on Upgrade
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.
Negative
Benzinga
2 months ago
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.
Neutral
Zacks Investment Research
2 months ago
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Charts implemented using Lightweight Charts™